Sellas Life Sciences: SLS009 Enrollment Hits 40 as REGAL Readout Nears
Published on 11/16/2026 at 19:50 | Editorial boerse-global.deSellas Life Sciences has enrolled 40 patients in its ongoing Phase 2 trial of SLS009 in newly diagnosed acute myeloid leukemia (AML), the company said Thursday. Preliminary topline data from that cohort are expected in the fourth quarter of 2026. Shares slipped 3.9% on the day.
The enrollment update covers one piece of a broader clinical puzzle. A separate presentation of Phase 2 data on the same drug candidate in relapsed or refractory AML is slated for the ASH annual meeting, running December 12–15. Sellas had already flagged encouraging response and survival findings in its November 4 announcement; the upcoming ASH session covers high-risk AML, and the positive framing originates with the company.
One Drug, Distinct Patient Populations
Those ASH data rest on a completed Phase 2 study of 62 patients who had received prior venetoclax-based therapy. In patients with relapsed or refractory monocytic AML, Sellas reported an overall response rate of 54% at the selected dose, with median overall survival of 5.8 months. For TP53-mutated AML at the same dose, the figures were a 57% overall response rate and 8.8 months of median overall survival.
The numbers describe the same treated population from different angles, and they belong to a specific treatment setting. That distinction matters: a response rate observed in one group of patients does not pre-empt the results of a trial still under way. The same molecule name does not make different clinical situations equivalent, and the completed study's findings should not be read as a preview of the newly diagnosed cohort now at 40 patients.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
REGAL's Own Clock
Galinpepimut-S, or GPS, follows a separate timetable. Sellas expects topline results on the primary endpoint of its Phase 3 REGAL trial in AML in November, a timeframe the company reiterated alongside its quarterly figures on Thursday. That expectation stands on its own and should not be folded into the SLS009 findings.
The financial picture forms yet another layer. Sellas ended September 30 with cash and cash equivalents of $134.7 million. For the quarter closed September 30, 2026, the company posted a net loss of $10.1 million, wider than the $6.8 million shortfall in the year-earlier period. A strong balance sheet is part of the funding runway, not a measure of any drug's efficacy.
State Street Discloses 5.1% Stake
Institutional ownership also shifted into view. A Schedule 13G filing shows State Street as a shareholder with roughly 10.4 million Sellas shares economically attributed to it, equal to 5.1% of the share class as of September 30, 2026.
Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.
For investors, the relevant exercise is to keep the questions apart: what has already been observed, in which patient group, and what is still pending. Sellas offers several clinical entry points, and their value lies not in being bundled into a single progress narrative but in the distinct contribution each study makes to judging its respective drug. The November REGAL readout and the fourth-quarter 2026 SLS009 data will each be measured on that basis.
Ad
Sellas Life Sciences Stock: New Analysis - 16 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
